Cantargia AB
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5
Ending by 2030
Mar 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 3, 2027The maintenance fee for Anti-IL1RAP antibodies and their use for treating humans (US 11,773,174) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.
- 1 fee due Aug 18, 2027The maintenance fee for Method of detection of IL1RAP on cells expressing the protein (US 10,562,971) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,715,619 | Compositions and methods for treating haematological proliferative disorders of myeloid origin In force · From the USPTO record | In force | From the USPTO record | |
| US 9,371,390 | Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,458,237 | Method for inducing cell death in acute lymphoblastic leukemic system cells In force · From the USPTO record | In force | From the USPTO record | |
| US 10,005,842 | Method of treatment for leukemia using an anti-IL1RAP antibody In force · From the USPTO record | In force | From the USPTO record | |
| US 10,878,703 | Method of treatment of leukemia with anti-IL1RAP antibodies In force · From the USPTO record | In force | From the USPTO record | |
| US 10,005,841 | Method of treating a solid tumor with IL1RAP antibodies In force · From the USPTO record | In force | From the USPTO record | |
| US 10,995,144 | Methods of detecting a solid tumor with anti-IL1RAP antibodies In force · From the USPTO record | In force | From the USPTO record | |
| US 9,403,906 | Method of treatment of a solid tumor with interleukin-1 accessory protein antibody In force · From the USPTO record | In force | From the USPTO record | |
| US 11,773,174 | Anti-IL1RAP antibodies and their use for treating humans In force · From the USPTO record | In force | From the USPTO record | |
| US 9,796,783 | Anti Human INTERLEUKIN-1 Receptor Accessory Protein (IL1 Rap) Antibodies and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 18: 2 patents in force now held by others · 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending